Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,909
  • Shares Outstanding, K 2,853
  • Annual Sales, $ 170 K
  • Annual Income, $ -17,320 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.19
  • Price/Sales 24.34
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.98
  • Number of Estimates 1
  • High Estimate -0.98
  • Low Estimate -0.98
  • Prior Year -10.00
  • Growth Rate Est. (year over year) +90.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +8.73%
on 11/21/25
1.6527 -17.11%
on 11/26/25
-0.2100 (-13.29%)
since 11/12/25
3-Month
1.2600 +8.73%
on 11/21/25
2.9800 -54.03%
on 09/23/25
-1.2300 (-47.31%)
since 09/12/25
52-Week
1.2600 +8.73%
on 11/21/25
36.0000 -96.19%
on 04/07/25
-19.9300 (-93.57%)
since 12/12/24

Most Recent Stories

More News
AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced the next  CEO Corner  segment has been published on the...

AIM : 1.3700 (-5.52%)
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series

OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer...

AIM : 1.3700 (-5.52%)
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”), today provided a business update and reported its financial results for...

AIM : 1.3700 (-5.52%)
accesso® to Showcase AI-Powered Shopping Preview and New Innovation at IAAPA Orlando 2025

The company's new conversational ordering and shopping capabilities join updates to Freedom, Passport, Horizon and LoQueue, highlighting the evolving connected accesso experience.

AIM : 1.3700 (-5.52%)
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase...

AIM : 1.3700 (-5.52%)
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant...

AIM : 1.3700 (-5.52%)
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced that the European Patent Office has officially granted...

AIM : 1.3700 (-5.52%)
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit ,...

AIM : 1.3700 (-5.52%)
Ascendiant Reaffirms Their Buy Rating on AIM ImmunoTech (AIM)

Ascendiant analyst Edward Woo maintained a Buy rating on AIM ImmunoTech on October 3 and set a price target of $24.00. The company’s shares closed last Friday at $2.64.Elevate Your Investing Strategy:...

AIM : 1.3700 (-5.52%)
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical...

AIM : 1.3700 (-5.52%)

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 1.5098
2nd Resistance Point 1.4699
1st Resistance Point 1.4199
Last Price 1.3700
1st Support Level 1.3300
2nd Support Level 1.2901
3rd Support Level 1.2401

See More

52-Week High 36.0000
Fibonacci 61.8% 22.7293
Fibonacci 50% 18.6300
Fibonacci 38.2% 14.5307
Last Price 1.3700
52-Week Low 1.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar